Exagen Reports Strong Preliminary 2025 Revenue Growth and Increased Cash Position
XGN has more than doubled off its 52-week low of $2.67.
Summary
Exagen Inc. reported strong preliminary 2025 financial results, including record revenue growth and a substantial increase in cash, indicating solid operational execution and improved financial health.
Key Events · Earnings and Guidance · XGN
-
Record Full-Year Revenue
Preliminary unaudited full-year 2025 revenue is projected to be $66M to $67M, representing 19% to 20% year-over-year growth.
-
Strong Cash Position
The company ended 2025 with $32M in cash and cash equivalents, a $10M increase from 2024.
-
Operational Growth
AVISE CTD test volume grew by 11% to 136,000-137,000, with average selling price expanding by at least $30 compared to 2024.
-
Guidance Alignment
The preliminary results are in line with the company's prior financial guidance.
Analysis · XGN · Industrial Applications And Services
Exagen Inc. announced preliminary unaudited financial results for 2025, highlighting record full-year revenue growth of 19-20% to $66M-$67M, in line with prior guidance. The company also significantly strengthened its balance sheet, ending the year with $32M in cash and cash equivalents, a $10M increase from the previous year. This strong financial performance, driven by increased AVISE CTD test volume and average selling price expansion, provides the company with enhanced flexibility to invest in innovation and pursue its goal of profitability.
At the time of this filing, XGN was trading at $6.45 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $139.8M. The 52-week trading range was $2.67 to $12.23. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.